5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 101–200 of 1,028
Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688377 · Cited by 250
Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans
Scott, T. A., Quintaneiro, L. M., Norvaisas, P., Lui, P. P., Wilson, M. P., Leung, K.-Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P. T., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.040 · Cited by 254
“See also E. coli or C. elegans (Figures 6C and 6D), the two metabolites responsible for impeding cellular division by causing RNA and DNA damage, respectively (Longley et al., 2003).”
BackgroundInfluentialA Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Graham, J., Muhsin, M., & Kirkpatrick, P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1287 · Cited by 251
Yan, S., Sorrell, M., & Berman, Z. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1666-4 · Cited by 247
“Furthermore, MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment, whereas FdU may be excised by the uracil glycosylase Smug1 to protect cells from death [210, 211].”
BackgroundParticipation of DNA repair in the response to 5-fluorouracil
Wyatt, M. D., & Wilson, D. M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8557-5 · Cited by 247
“We refer readers to other reviews that cover aspects of 5-FU metabolism, including incorporation of 5-FU into RNA and suicide inhibition of TS [9,10,14].”
BackgroundMethodSelf-assembled metal–organic polyhedra: An overview of various applications
Vardhan, H., Yusubov, M., & Verpoort, F. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.05.016 · Cited by 243
Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics
García-González, A. P., Ritter, A. D., Shrestha, S., Andersen, E. C., Yilmaz, L. S., & Walhout, A. J. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.046 · Cited by 243
“The observation that thymine fails to rescue the anti-pyrimidine drug effects indicates that inhibition of thymidylate synthase may not be the principal mechanism of action (Longley et al., 2003).”
BackgroundInfluentialDrug-induced oxidative stress in cancer treatments: Angel or devil?
Jiang, H., Zuo, J., Li, B., Chen, R., Luo, K., Xiang, X., Lu, S., Huang, C., Liu, L., Tang, J., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102754 · Cited by 231
Wang, J.-Q., Yang, Y., Cai, C.-Y., Teng, Q.-X., Cui, Q., Lin, J., Assaraf, Y. G., & Chen, Z.-S. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100743 · Cited by 241
Cartman, S. T., Kelly, M. L., Heeg, D., Heap, J. T., & Minton, N. P. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.00249-12 · Cited by 242
“ration of fluorinated nucleotides into DNA and RNA (17, 21).”
BackgroundInfluentialFluorine and Gold: A Fruitful Partnership
Miró, J., & del Pozo, C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00203 · Cited by 234
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer
Madak, J. T., Bankhead, A., Cuthbertson, C. R., Showalter, H. D., & Neamati, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.012 · Cited by 225
Colon cancer: Cancer stem cells markers, drug resistance and treatment
Kozovska, Z., Gabrisova, V., & Kucerova, L. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.019 · Cited by 228
Boyer, J., McLean, E. G., Aroori, S., Wilson, P., McCulla, A., Carey, P. D., Longley, D. B., & Johnston, P. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0362 · Cited by 229
“TS is a major cellular target of 5-FU, and DPD catalyzes the rate-limiting step in the catabolism of 5-FU (33).”
BackgroundSelf-citationTP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.007 · Cited by 226
“Nonanthracyclinebased DNA-damaging therapies are broader in mechanism of action and include DNAalkylating agents like cyclophosphamide [14] and antimetabolites like 5-fluorouracil that interfere with DNA synthesis [15].”
BackgroundFluorine-containing drugs approved by the FDA in 2019
Mei, H., Remete, A. M., Zou, Y., Moriwaki, H., Fustero, S., Kiss, L., Soloshonok, V. A., & Han, J. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.050 · Cited by 225
Serine, glycine and one‑carbon metabolism in cancer (Review)
Pan, S., Fan, M., Liu, Z., Li, X., & Wang, H. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5158 · Cited by 227
Exploiting DNA Replication Stress for Cancer Treatment
Ubhi, T., & Brown, G. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3631 · Cited by 230
“For example, gemcitabine potentiates its cytotoxic effects by also inhibiting ribonucleotide reductase (29), whereas 5-fluorouracil functions mainly by inhibiting thymidylate synthetase, thereby reducing the amount of thymidine available for DNA replication and repair (30).”
BackgroundImpact of Dendrimers on Solubility of Hydrophobic Drug Molecules
Choudhary, S., Gupta, L., Rani, S., Dave, K., & Gupta, U. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00261 · Cited by 221
A non-proliferative role of pyrimidine metabolism in cancer
Siddiqui, A., & Ceppi, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.02.005 · Cited by 228
Promise and challenges in drug discovery and development of hybrid anticancer drugs
Gediya, L. K., & Njar, V. C. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903341705 · Cited by 222
“6 5-Fluorouracil–cytarabine (11) The chemotherapy agent 5-Fluorouracil (5-FU) [54], which has been in use against cancer for about 40 years, acts in several ways, but principally as a thymidylate synthase inhibitor.”
BackgroundKong, J., Lee, H., Kim, D., Han, S. K., Ha, D., Shin, K., & Kim, S. (2020) · Nature Communications · doi:10.1038/s41467-020-19313-8 · Cited by 212
Genital warts: a comprehensive review.
Yanofsky, V. R., Patel, R. V., & Goldenberg, G. (2012) · Europe PMC (PubMed Central) · Cited by 226
Dysregulation of the basal RNA polymerase transcription apparatus in cancer
Bywater, M. J., Pearson, R. B., McArthur, G. A., & Hannan, R. D. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3496 · Cited by 222
Sgambellone, M. A., David, A., Garner, R. N., Dunbar, K. R., & Turro, C. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4045604 · Cited by 217
Swift, L., & Golsteyn, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033403 · Cited by 213
“The fluoropyrimidine 5-fluorouracil (5-FU) (Figure 2H) is an antimetabolite commonly used to treat colorectal cancers [64].”
InfluentialMacias, E., Jin, A., Deisenroth, C., Bhat, K., Mao, H., Lindström, M. S., & Zhang, Y. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.007 · Cited by 216
“5-FU is a pyrimidine analog whose metabolite, FUTP, is extensively incorporated into RNA, disrupting normal RNA processing (Longley et al., 2003).”
Dihydropyrimidine Dehydrogenase Gene as a Major Predictor of Severe 5-Fluorouracil Toxicity
Amstutz, U., Froehlich, T. K., & Largiadèr, C. R. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.72 · Cited by 217
Kumar, R., Han, J., Lim, H.-J., Ren, W. X., Lim, J.-Y., Kim, J.-H., & Kim, J. S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja510421q · Cited by 214
Three‐dimensional cell culture models for anticancer drug screening: Worth the effort?
Verjans, E., Doijen, J., Luyten, W., Landuyt, B., & Schoofs, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26052 · Cited by 212
The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC)
Basak, D., Uddin, M. N., & Hancock, J. (2020) · Cancers · doi:10.3390/cancers12113336 · Cited by 211
“An increased level of intracellular ROS was evident in colon cancer cells that are 5-fluorouracil (5-FU) resistant [174].”
BackgroundLiu, K., Zhang, X., Xie, L., Deng, M., Chen, H., Song, J., Long, J., Li, X., & Luo, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105373 · Cited by 198
Pseudouridine: Still mysterious, but never a fake (uridine)!
Spenkuch, F., Motorin, Y., & Helm, M. (2014) · RNA Biology · doi:10.4161/15476286.2014.992278 · Cited by 209
Yuan, L., Zhang, S., Li, H., Yang, F., Mushtaq, N., Ullah, S., Shi, Y., An, C., & Xu, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.165 · Cited by 208
Mariadason, J. M., Arango, D., Shi, Q., Wilson, A. J., Corner, G. A., Nicholas, C., Aranes, M., LESSER, M. L., Schwartz, E. L., & Augenlicht, L. H. (2003) · PubMed · Cited by 223
Angelis, P. M. D., Kravik, K., Tunheim, S. H., Haug, T., & Reichelt, W. H. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-11 · Cited by 210
“The main mechanism of action of 5-FU is to inhibit thymidylate synthase, a key enzyme in the de novo synthesis of dTMP from dUMP [2,6].”
BackgroundMethodThe dual role of thymidine phosphorylase in cancer development and chemotherapy
Bronckaers, A., Gago, F., Balzarini, J., & Liekens, S. (2009) · Medicinal Research Reviews · doi:10.1002/med.20159 · Cited by 206
“Alternatively, 5FU may be converted directly or indirectly to 5fluorouridine 50-monophosphate (FUMP), which can be incorporated into RNA (upon conversion to its 50-triphosphate derivative), resulting in inhibition of protein synthesis.(328) The direct conversion of 5FU to FUMP by orotate phosphoribosyl transferase (OP…”
BackgroundGuo, J., Yu, Z., Das, M., & Huang, L. (2020) · ACS Nano · doi:10.1021/acsnano.0c01676 · Cited by 203
Yang, M., Luo, Q., Chen, X., & Chen, F. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00995-1 · Cited by 194
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death
Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., & Johnston, P. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209122 · Cited by 202
“The fluoropyrimidine 5-fluorouracil (5-FU) has been the mainstay of colorectal cancer (CRC) therapy for over 40 years (Longley et al., 2003).”
BackgroundSelf-citationMetabolism and Colorectal Cancer
Sedlak, J. C., Yilmaz, Ö. H., & Roper, J. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-041113 · Cited by 191
5-Fluorouracil treatment induces characteristic T>G mutations in human cancer
(2019) · doi:10.1038/s41467-019-12594-8 · Cited by 201
Spliceosomal snRNA modifications and their function
Karijolich, J., & Yu, Y.-T. (2010) · RNA Biology · doi:10.4161/rna.7.2.11207 · Cited by 204
Mechanisms of apoptosis induction by nucleoside analogs
Sampath, D., Rao, V. A., & Plunkett, W. (2003) · Oncogene · doi:10.1038/sj.onc.1207229 · Cited by 199
“The ribonucleoside triphosphate of 5-fluorouracil, FUTP, may be incorporated into RNA, and affect the function of transcripts (Longley et al., 2003).”
BackgroundThe enigmatic thymine DNA glycosylase
CORTAZAR, D., KUNZ, C., SAITO, Y., STEINACHER, R., & SCHAR, P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2006.10.013 · Cited by 199
“[105] D.”
BackgroundGut Microbiota Shapes the Efficiency of Cancer Therapy
Ma, W., Mao, Q., Xia, W., Dong, G., Yu, C., & Jiang, F. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01050 · Cited by 192
“5-FU interferes with the synthesis of thymidylate and inhibits DNA synthesis during DNA replication and repair (Longley et al., 2003).”
BackgroundCancer pharmacogenetics: polymorphisms, pathways and beyond
Ulrich, C. M., Robien, K., & McLeod, H. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1233 · Cited by 199
Borralho, P. M., Kren, B. T., Castro, R. E., Moreira da Silva, I. B., Steer, C. J., & Rodrigues, C. M. P. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07383.x · Cited by 195
5-Fluorouracil Activation of p53 Involves an MDM2-Ribosomal Protein Interaction
Sun, X.-X., Dai, M.-S., & Lu, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610621200 · Cited by 199
Deoxyribonucleotide metabolism, mutagenesis and cancer
Mathews, C. K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3981 · Cited by 198
Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer
Long, F., Lin, Z., Li, L., Ma, M., Lu, Z., Jing, L., Li, X., & Lin, C. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01318-6 · Cited by 198
Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S. A., Basiri, A., & Taheri, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658636 · Cited by 193
“F l u o r o d e o x y u r i d i n e monopho s p h a t e ( F dUMP ) , fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate (FUTP) are all the final active metabolites of 5FU which are produced after the active transportation of 5-FU into cells by the uracil transport system (15, 16) in addition to th…”
BackgroundNie, J., Liu, L., Zheng, W., Chen, L., Wu, X., Xu, Y., Du, X., & Han, W. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr245 · Cited by 193
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Wu, H.-L., Gong, Y., Ji, P., Xie, Y.-F., Jiang, Y.-Z., & Liu, G.-Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01263-x · Cited by 186
“Then, 5-FU received FDA approval in 1960 [144–146], and it currently has further extensive indications for various malignancies, such as gastrointestinal cancer, breast cancer, and renal cell cancer [108, 147].”
BackgroundGao, Y., Xiao, X., Zhang, C., Yu, W., Guo, W., Zhang, Z., Li, Z., Feng, X., Hao, J., Zhang, K., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12380 · Cited by 189
pH-Sensitive nanoscale materials as robust drug delivery systems for cancer therapy
Shi, Z., Li, Q., & Mei, L. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.001 · Cited by 188
Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis
Wei, Z., Song, J., Wang, G., Cui, X., Zheng, J., Tang, Y., Chen, X., Li, J., Cui, L., Liu, C.-Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06812-y · Cited by 185
Emerging role of NRF2 in ROS-mediated tumor chemoresistance
Xue, D., Zhou, X., & Qiu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110676 · Cited by 191
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., Opatrilova, R., Kruzliak, P., Stefanicka, P., & Büsselberg, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.108 · Cited by 184
Methionine Restriction and Cancer Biology
Wanders, D., Hobson, K., & Ji, X. (2020) · Nutrients · doi:10.3390/nu12030684 · Cited by 185
“Importantly, MR also enhanced efficacy of 5‐fluorouracil, a chemotherapeutic drug with great efficacy against colorectal cancer [92], in the PDX model [12].”
BackgroundWu, X., He, C., Wu, Y., & Chen, X. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.016 · Cited by 186
Wang, H.-N., Meng, X., Yang, G.-S., Wang, X.-L., Shao, K.-Z., Su, Z.-M., & Wang, C.-G. (2011) · Chemical Communications · doi:10.1039/c1cc11932j · Cited by 185
Boussios, S., Pentheroudakis, G. E., Katsanos, K. H., & Pavlidis, N. A. (2012) · PubMed Central · Cited by 200
Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance
Raghunath, A., Sundarraj, K., Arfuso, F., Sethi, G., & Perumal, E. (2018) · Cancers · doi:10.3390/cancers10120481 · Cited by 186
“5-FU induces apoptosis in cancer cells through the depletion of antioxidants and hence is used as a chemotherapeutic agent against various cancers [171].”
BackgroundRecent Advances in Stimuli-Responsive Release Function Drug Delivery Systems for Tumor Treatment
Ding, C., Tong, L., Feng, J., & Fu, J. (2016) · Molecules · doi:10.3390/molecules21121715 · Cited by 181
“MOFs Carboxylatopillararene based pseudo[2]rotaxanes gatekeeper DOX Acid-induced disassembly of pseudorotaxane gatekeeper pH-sensitive drug release, negligible intrinsic cytotoxicity [124]”
BackgroundMethodInfluentialEntezar-Almahdi, E., Mohammadi-Samani, S., Tayebi, L., & Farjadian, F. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s257700 · Cited by 181
Wang, T.-L., Diaz, L. A., Romans, K., Bardelli, A., Saha, S., Galizia, G., Choti, M., Donehower, R., Parmigiani, G., Shih, I.-M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308716101 · Cited by 183
Overview of Tumor Cell Chemoresistance Mechanisms
Gatti, L., & Zunino, F. (2005) · Chemosensitivity · doi:10.1385/1-59259-889-7:127 · Cited by 179
Automated Modular Synthesis of Aptamer–Drug Conjugates for Targeted Drug Delivery
Wang, R., Zhu, G., Mei, L., Xie, Y., Ma, H., Ye, M., Qing, F.-L., & Tan, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4117395 · Cited by 181
Arya, G. C., Kaur, K., & Jaitak, V. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113511 · Cited by 170
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
Adamska, A., Elaskalani, O., Emmanouilidi, A., Kim, M., Abdol Razak, N. B., Metharom, P., & Falasca, M. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.11.007 · Cited by 183
H3K27me3 conditions chemotolerance in triple-negative breast cancer
Marsolier, J., Prompsy, P., Durand, A., Lyne, A.-M., Landragin, C., Trouchet, A., Bento, S. T., Eisele, A., Foulon, S., Baudre, L., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01047-6 · Cited by 178
Beyond matrix stiffness: targeting force-induced cancer drug resistance
Kalli, M., Poskus, M. D., Stylianopoulos, T., & Zervantonakis, I. K. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.006 · Cited by 167
“5-FU incorporates into DNA to inhibit DNA and RNA synthesis [19], whereas gemcitabine also induces DNA damage to prevent DNA replication [20].”
BackgroundCancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2106) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 177
“The fluoropyrimidine 5-FU is widely used in the treatment of a variety of cancers, including colorectal, breast, and aerodigestive tract cancer [88].”
BackgroundUracil in DNA—General mutagen, but normal intermediate in acquired immunity
KAVLI, B., OTTERLEI, M., SLUPPHAUG, G., & KROKAN, H. (2007) · DNA Repair · doi:10.1016/j.dnarep.2006.10.014 · Cited by 178
Controlled Drug Delivery Systems for Oral Cancer Treatment—Current Status and Future Perspectives
Ketabat, F., Pundir, M., Mohabatpour, F., Lobanova, L., Koutsopoulos, S., Hadjiiski, L., Chen, X., Papagerakis, P., & Papagerakis, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070302 · Cited by 173
“This drug has been effective in treating various types of cancer, including oral, head and neck cancer, colorectal, and breast cancer [80].”
BackgroundLaCourse, K. D., Zepeda-Rivera, M., Kempchinsky, A. G., Baryiames, A., Minot, S. S., Johnston, C. D., & Bullman, S. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111625 · Cited by 173
Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age
Ferreira, R., Schneekloth, J. S., Panov, K. I., Hannan, K. M., & Hannan, R. D. (2020) · Cells · doi:10.3390/cells9020266 · Cited by 183
“The combination of these attributes leads to both RNA and DNA damage and consequently the death of cancer or normal cells (reviewed by Longley et al [62]).”
BackgroundA synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
Chung, Y., Ryu, Y., An, B. C., Yoon, Y.-S., Choi, O., Kim, T. Y., Yoon, J., Ahn, J. Y., Park, H. J., Kwon, S.-K., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01071-4 · Cited by 172
“However, it is rapidly inactivated by cytidine deaminase [31] or deoxycytidylate deaminase [34] before being delivered to the target site, and thus inappropriate for systemic therapy.”
BackgroundMethodYeung, C.-Y., Chan, W.-T., Jiang, C.-B., Cheng, M.-L., Liu, C.-Y., Chang, S.-W., Chiang Chiau, J.-S., & Lee, H.-C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138746 · Cited by 176
“The anti-metabolite 5-Fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in clinical oncology due to its ability to exert its cytotoxic effects through incorporation into RNA and DNA and finally inhibit DNA synthesis and to improve tumor-free status and survival rates.[1] However, studies est…”
BackgroundCell-Type-Specific Responses to Chemotherapeutics in Breast Cancer
Troester, M. A., Hoadley, K. A., Sørlie, T., Herbert, B.-S., Børresen-Dale, A.-L., Lønning, P. E., Shay, J. W., Kaufmann, W. K., & Perou, C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0107 · Cited by 179
“Finally, we note that DOX and 5FU have distinct mechanisms of action (41, 42).”
BackgroundPredictive Markers in Breast and Other Cancers: A Review
Duffy, M. J. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046227 · Cited by 174
Kucerova, L., Matuskova, M., Pastorakova, A., Tyciakova, S., Jakubikova, J., Bohovic, R., Altanerova, V., & Altaner, C. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1239 · Cited by 171
“5FU metabolism and resistance [27,28] revealed that both low passage and high passage AT-MSC express”
BackgroundDrug resistance, predictive markers and pharmacogenomics in colorectal cancer
Longley, D. B., Allen, W. L., & Johnston, P. G. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.001 · Cited by 171
Self-citationThe role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
Feng, X., Luo, Q., Zhang, H., Wang, H., Chen, W., Meng, G., & Chen, F. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0553-x · Cited by 170
“effective and commonly used drugs for OSCC [5].”
BackgroundOne-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy
Shuvalov, O., Petukhov, A., Daks, A., Fedorova, O., Vasileva, E., & Barlev, N. A. (2017) · Oncotarget · doi:10.18632/oncotarget.15053 · Cited by 168
“To enhance the efficiency of 5-FU binding to TS another drug, Leucovorin, is often used as an adjuvant therapy [151].”
BackgroundtRNA Modifying Enzymes, NSUN2 and METTL1, Determine Sensitivity to 5-Fluorouracil in HeLa Cells
Okamoto, M., Fujiwara, M., Hori, M., Okada, K., Yazama, F., Konishi, H., Xiao, Y., Qi, G., Shimamoto, F., Ota, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004639 · Cited by 168
“cycle arrest and apoptosis in cancer cells [1].”
BackgroundZhang, H., Tang, J., Li, C., Kong, J., Wang, J., Wu, Y., Xu, E., & Lai, M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.10.029 · Cited by 166
Chronotherapy and the molecular clock: Clinical implications in oncology☆
Innominato, P. F., Lévi, F. A., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 164
Almqvist, H., Axelsson, H., Jafari, R., Dan, C., Mateus, A., Haraldsson, M., Larsson, A., Molina, D. M., Artursson, P., Lundbäck, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11040 · Cited by 160
Zhang, H., Li, R., Cao, Y., Gu, Y., Lin, C., Liu, X., Lv, K., He, X., Fang, H., Jin, K., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000004037 · Cited by 168
“Keywords: adjuvant chemotherapy, gastric cancer, immune evasion, interleukin-10, macrophages, prognosis (Ann Surg 2022;275:e626–e635) G astric cancer ranks the fifth most frequently diagnosed malig-nancy and the third leading cause of cancer-related mortality in the world.1 Radical gastrectomy is generally considered…”
BackgroundInfluentialDefining principles of combination drug mechanisms of action
Pritchard, J. R., Bruno, P. M., Gilbert, L. A., Capron, K. L., Lauffenburger, D. A., & Hemann, M. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210419110 · Cited by 168
“Leucovorin (which on its own is nontoxic) exerts a synergistic effect by enhancing the inhibition of thymidylate synthase by the nucleoside analog 5-FU (22); this inhibition depletes cellular nucleotide levels and induces apoptosis.”
BackgroundTAS-102, a novel antitumor agent: A review of the mechanism of action
Lenz, H.-J., Stintzing, S., & Loupakis, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.001 · Cited by 163
“Agents that target nucleoside metabolism have been pivotal to the treatment of cancer for decades and are still the basis of chemotherapeutic treatment in multiple neoplasms, such as 5-FU for colon and breast cancer and pemetrexed for lung cancer, and a number of new antimetabolites are currently in development for cl…”
BackgroundInfluentialTargeting the DNA Damage Response in Cancer
Ljungman, M. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 163
Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance
Pothuraju, R., Rachagani, S., Krishn, S. R., Chaudhary, S., Nimmakayala, R. K., Siddiqui, J. A., Ganguly, K., Lakshmanan, I., Cox, J. L., Mallya, K., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01156-y · Cited by 160
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J. E., Storrie-White, H., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E.-J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 156
Brown, J. A., Yonekubo, Y., Hanson, N., Sastre-Perona, A., Basin, A., Rytlewski, J. A., Dolgalev, I., Meehan, S., Tsirigos, A., Beronja, S., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.10.001 · Cited by 158
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.